Skip to main content
SpringerLink
Log in

The Surgeon’s Perspective on Hepatic Radiofrequency Ablation

  • Chapter
Tumor Ablation

  • 2695 Accesses

Abstract

Surgeons continue to have an important role in the management of patients with hepatic malignancies. Throughout the decades, modern surgical techniques have improved outcomes in patients undergoing hepatic surgery. However, the majority of hepatic malignancies continue to be unamenable to surgical resection. These patients continue to be challenging for clinicians. Surgeons have carried out hepatic tumor ablation since the 1970s; therefore, a vast experience has been gained in terms of techniques, outcomes, and patient selection for tumor ablation. Cryosurgical ablation has been performed for the past several decades, and long-term patient outcome data currently are available. The experience and outcome with cryoablation can be extrapolated to more modern modalities of tumor ablation, such as with radiofrequency energy. In the early 1990s, developments in laparoscopic surgery influenced hepatic surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wingo P, Tong T, Bolden S. Cancer Statistics, 1995. CA Cancer J, Clin 1995;45:8.

    Article  CAS  Google Scholar 

  2. Wagner JS, Adson MA, van Heerdon JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984;199:502–508.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Fong Y, Blumgart LH. Hepatic colorectal metastases: current status of surgical therapy. Oncology 1998;12:1489–1498.

    PubMed  CAS  Google Scholar 

  4. Stangl R, Altendof-Hoffman A, Charnley RM, et al. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343: 1404–1410.

    Article  Google Scholar 

  5. Scheithauer W, Rosen H, Kornkek GV, et al. Randomised comparison of combination chemotherapy plus supportive care in patients with metastatic colorectal cancer. BMJ 1993;306:752–755.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant chemotherapy of resected colon carcinoma. N Engl J Med 1990;322:352–358.

    Article  PubMed  CAS  Google Scholar 

  7. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355:1041–1047.

    Article  PubMed  CAS  Google Scholar 

  8. Rougier P, Van Cutsem E, Bajetta E, et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407–1412.

    Article  PubMed  CAS  Google Scholar 

  9. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–915.

    Article  PubMed  CAS  Google Scholar 

  10. Cunningham D, Pyrhonen S, James RD, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413–1418.

    Article  PubMed  CAS  Google Scholar 

  11. de Gramont R, Figer A, Seymore M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment for advanced colorectal cancer. J Clin Oncol 2000;18:2938–2947.

    PubMed  Google Scholar 

  12. Levi F, Zidani R, Vannetzel JM, et al. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997;350:681–686.

    Article  PubMed  CAS  Google Scholar 

  13. Giachetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and surgery. Ann Oncol 1999;10: 663–669.

    Article  Google Scholar 

  14. Shaheen RM, Ahmed SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85:584–589.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Chang AE, Schneider PD, Sugerbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685–693.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112–1118.

    PubMed  CAS  Google Scholar 

  17. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000;18:243–254.

    PubMed  CAS  Google Scholar 

  18. Kemeny N, Gonen M, Sullivan D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from metastatic colon cancer. J Clin Oncol 2001;19:2687–2695.

    PubMed  CAS  Google Scholar 

  19. Scheele J, Stangl R, Altendorf-Hofman A. Hepatic metastases from colorectal cancer: impact of surgical resection on the natural history. Br J Surg 1990;77:1241–1246.

    Article  PubMed  CAS  Google Scholar 

  20. Bradley AL, Chapman WC, Wright JK, et al. Surgical experience with hepatic colorectal metastasis. Am Surg 1999;65:560–566.

    PubMed  CAS  Google Scholar 

  21. Harmon KE, Ryan JAJ, Beihl TR, et al. Benefits and safety of hepatic resection for colorectal metastases. Am J Surg 1999;177:402–404.

    Article  PubMed  CAS  Google Scholar 

  22. Nagashima I, Oka T, Hamada C, et al. Histopathological prognostic factors influencing long-term prognosis after surgical resection for hepatic metastases from colorectal cancer. Am J Gastroenterol 1999;94:739–743.

    Article  PubMed  CAS  Google Scholar 

  23. Taylor M, Forster J, Langer B, et al. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg 1997;173:467–471.

    Article  PubMed  CAS  Google Scholar 

  24. Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin North Am 2003; 162–192.

    Google Scholar 

  25. Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997;132:505–510.

    Article  PubMed  CAS  Google Scholar 

  26. Ohlsson B, Stenram U, Tranberg KG, et al. Resection of colorectal metastases: 25-year experience. World J Surg 1998;22:268–276.

    Article  PubMed  CAS  Google Scholar 

  27. Holm A, Bradley E, Aldrete JS. Hepatic resection of metastases from colorectal carcinoma. Morbidity, mortality, and pattern of recurrence. Ann Surg 1989;209:428–434.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–318.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Bismuth H, Adam R, Navarro F, et al. Re-resection for colorectal liver metastases. Surg Oncol Clin North Am 1996;5:353–364.

    CAS  Google Scholar 

  30. Nakamura S, Sakaguchi S, Nishiyama R, et al. Aggressive repeat liver resection for hepatic metastases of colorectal carcinoma. Surg Today 1992;22:260–264.

    Article  PubMed  CAS  Google Scholar 

  31. Ekberg H, Tranberg KG, Andersson R, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986;73:727–731.

    Article  PubMed  CAS  Google Scholar 

  32. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001;5:87–107.

    Article  PubMed  CAS  Google Scholar 

  33. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271–285.

    Article  PubMed  CAS  Google Scholar 

  34. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160:3227–3230.

    Article  PubMed  CAS  Google Scholar 

  35. Chu CM. Natural history of chronic hepatitis B virus in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15(suppl):E25–E30.

    Article  PubMed  Google Scholar 

  36. Colombo M. Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis 1999;19:263–269.

    Article  PubMed  CAS  Google Scholar 

  37. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998;28:930–938.

    Article  PubMed  CAS  Google Scholar 

  38. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001;33:62–65.

    Article  PubMed  CAS  Google Scholar 

  39. Nerenstone SR, Ihde DC, Freidman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988;15:1–31.

    Article  PubMed  CAS  Google Scholar 

  40. Heneghan MA, O’Grady JG. Liver transplantation of malignant liver disease. Ballieres Clin Gastroenterol 1999;13:575–591.

    CAS  Google Scholar 

  41. Patt YZ, Hassan NM, Lozano RD, et al. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000;23:319–321.

    Article  PubMed  CAS  Google Scholar 

  42. Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomized controlled trial. Gut 1998;42:442–447.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  43. Ahrar K, Gupta S. Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes. Surg Oncol Clin North Am 2003;12:105–126.

    Article  Google Scholar 

  44. Group d’Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of ethiodized oil chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256–1261.

    Google Scholar 

  45. Bruix J, Llovet JM, Castells A, et al. Transarterial chemoembolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized controlled trial in a single institution. Hepatology 1998;27:1578–1583.

    Article  PubMed  CAS  Google Scholar 

  46. Nagorney DM, Gigot JF. Primary epithelial hepatic malignancies: etiology, epidemiology, and outcome after subtotal and total hepatic resection. Surg Oncol Clin North Am 1996;5:283–300.

    CAS  Google Scholar 

  47. Fong Y, Sun RL, Jarnigin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229:790–799.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  48. Belghiti J, Panis Y, Farges O, et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991;214:114–117.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  49. Ravikumar TS. Interstitial therapies for liver tumors. Surg Oncol Clin North Am 1996;5:365–377.

    CAS  Google Scholar 

  50. LeVeen RF. Laser hyperthermia and radiofrequency ablation of hepatic lesions. Semin Intervent Radiol 1997;14:313–324.

    Google Scholar 

  51. Siperstein A, Gitomirsky A. History and technological aspects of radiofrequency thermoablation. Cancer J 2000;6(suppl):S293–303.

    Google Scholar 

  52. Adson MA, van Heerden JA. Adson MH, et al. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984;119:647–651.

    Article  PubMed  CAS  Google Scholar 

  53. Kane RA, Hughes LA, Cua EJ, et al. The impact of intraoperative ultrasonography on surgery for liver neoplasms. J Ultrasound Med 1994;13:1–6.

    PubMed  CAS  Google Scholar 

  54. de Baere T, Bessoud B, Dromaine C. Percutaneous radiofrequency ablation of hepatic tumors during temporary hepatic venous occlusion. AJR 2002;178:53–59.

    Article  PubMed  Google Scholar 

  55. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies; results of 123 patients. Ann Surg 1999;230:1–11.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  56. Scaife CL, Curley SA. Complication, local recurrence, and survival rates after radiofrequency ablation for hepatic malignancies. Surg Oncol Clin North Am 2003;12:243–255.

    Article  Google Scholar 

  57. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 2000;214:761–768.

    Article  PubMed  CAS  Google Scholar 

  58. Iannitti DA, Dupuy DE, Mayo-Smith WW, et al. Hepatic radiofrequency ablation. Arch Surg 2002;137:422–427.

    Article  PubMed  Google Scholar 

  59. Shaflr M, Shapiro R, Sung M, et al. Cryoablation of unresectable malignant liver tumors. Am J Surg 1996;171:27–31.

    Article  Google Scholar 

  60. Weaver ML, Ashton JG, Zemel R. Treatment of colorectal liver metastases by cryotherapy. Semin Surg Oncol 1998;14:163–170.

    Article  PubMed  CAS  Google Scholar 

  61. Tanden VR, Harmantas A, Gallinger S. Long-term survival after hepatic cryotherapy versus surgical resection for metastatic colorectal carcinoma: a critical review of the literature. Can J Surg 1997;40:175–181.

    Google Scholar 

  62. Ravikumar TS, Cady B, Jenkins R, et al. A 5-year study of cryosurgery in the treatment of liver tumors. Arch Surg 1991;126:1520–1524.

    Article  PubMed  CAS  Google Scholar 

  63. Zhou XD, Tang ZY, Yu YQ, et al. The role of cryosurgery in the treatment of hepatic cancer: a report of 113 cases. J Cancer Res Clin Oncol 1993;102:100–102.

    Article  Google Scholar 

  64. Zhou XD, Tang ZY, Yu YQ. Ablative approach for primary liver cancer. Surg Oncol Clin North Am 1996;5:370–390.

    Google Scholar 

  65. Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanaugh PV, Safran H. Percutaneous RF ablation of malignancies in the lung. AJR 2000;174:57–60.

    Article  PubMed  CAS  Google Scholar 

  66. Jeffrey SS, Birdwell RL, Ikeda DM, et al. Radiofrequency ablation of breast cancer: first report of an emerging technology. Arch Surg 1999;134:1064–1068.

    Article  PubMed  CAS  Google Scholar 

  67. Gervais DA, McGovern FJ, Wood BJ, et al. Radio-frequency ablation of renal cell carcinoma: early clinical experience. Radiology 2000; 217:665–672.

    Article  PubMed  CAS  Google Scholar 

  68. Rossi S, Buscarini E, Garbagnati F, et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR 1998;170(4):1015–1022.

    Article  PubMed  CAS  Google Scholar 

  69. Jiao LR, Hansen PD, Havlik R, et al. Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors. Am J Surg 1999;177(4):303–306.

    Article  PubMed  CAS  Google Scholar 

  70. Solbiati L, Ierace T, Goldberg SN, et al. Percutaneous US-guided radiofrequency ablation of liver metastases: treatment and follow-up in 16 patients. Radiology 1997;202:195–203.

    Article  PubMed  CAS  Google Scholar 

  71. Francica G, Marone G. Ultrasound-guided percutaneous treatment of hepatocellular carcinoma by radiofrequency hyperthermia with a “cooled-tip needle.” A preliminary clinical experience. Eur J Ultrasound 1999;9(2):145–153.

    Article  PubMed  CAS  Google Scholar 

  72. Solbiati L, Livraghi T, Goldberg, et al. Percutaneous radiofrequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001;221:159–166.

    Article  PubMed  CAS  Google Scholar 

  73. Bilchik AJ, Wood TF, Allegra D, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms. Arch Surg 2000;135(6):657–662.

    Article  PubMed  CAS  Google Scholar 

  74. Jarnagin WR, Fong Y, Ky A, et al. Liver resection for metastatic colon cancer: assessing the risk of occult irresectable disease. J Am Coll Surg 1999; 188(1):33–42.

    Article  PubMed  CAS  Google Scholar 

  75. Kokudo N, Bandai Y, Imanishi H, et al. Management of new hepatic nodules detected by intraoperative ultrasonography during hepatic resection for hepatocellular carcinoma. Surgery 1996;119:634–640.

    Article  PubMed  CAS  Google Scholar 

  76. Lo CM, Lai ECS, Liu CL, et al. Laparoscopy and laparoscopic ultrasound avoid exploratory laparotomy in patients with hepatocellular carcinoma. Ann Surg 1998;227:527–532.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  77. Shibata T, Iimuro Y, Ikai I, et al. Percutaneous radiofrequency ablation therapy after intrathoracic saline solution infusion for liver tumor in the hepatic dome. J Vasc Intervent Radiol 2002;13(3):313–315.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Rhode Island Hospital, Brown University, Providence, RI, USA

    David A. Iannitti MD (Assistant Professor of Surgery)

Authors
  1. David A. Iannitti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA

    Eric vanSonnenberg MD (Chief of Radiology, Interventional Radiologist) (Chief of Radiology, Interventional Radiologist)

  2. Brigham and Women’s Hospital Children’s Hospital, Boston, MA, 02115, USA

    Eric vanSonnenberg MD (Chief of Radiology, Interventional Radiologist) (Chief of Radiology, Interventional Radiologist)

  3. Boston, MA, 02115, USA

    William N. McMullen (Interventional Oncology Consultant) (Interventional Oncology Consultant)

  4. Department of Radiology, Ospedale Civile Busto Arsizio, 21052, Busto Arsizio, Italy

    Luigi Solbiati MD (Chairman) (Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Iannitti, D.A. (2005). The Surgeon’s Perspective on Hepatic Radiofrequency Ablation. In: vanSonnenberg, E., McMullen, W.N., Solbiati, L., Livraghi, T., Müeller, P.R., Silverman, S.G. (eds) Tumor Ablation. Springer, New York, NY. https://doi.org/10.1007/0-387-28674-8_41

Download citation

  • DOI: https://doi.org/10.1007/0-387-28674-8_41

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-95539-1

  • Online ISBN: 978-0-387-28674-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation